Results for this period
First quarter1 July 2026–30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
In the active pharmaceutical ingredients sales business, sales of products for cardiovascular and sensory organ applications, among others, declined, while in the pharmaceutical manufacturing and marketing business, sales of tablets for core products decreased. Meanwhile, sales of prefilled syringe products and other products increased.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 July 2026–30 September 2026 |
| Net Sales | ¥5,771 million (YoY -3.0%) |
| Operating profit | ¥1,113 million (YoY -17.7%) |
| Ordinary income | ¥1,142 million (YoY -14.8%) |
| Profit attributable to owners of the parent | ¥777 million (YoY -12.8%) |
| Net income per share | ¥18.46 |
| Equity ratio | End of the current fiscal period 79.6 / End of previous period 78.9 |
| Total assets | ¥39,082 million |
| Net assets | ¥31,125 million |
| Full-year earnings forecast | Net Sales ¥26,700 million (YoY +8.2%) / Operating profit ¥5,270 million (YoY -3.8%) / Ordinary income ¥5,260 million (YoY -4.7%) / Net income ¥3,590 million (YoY -4.2%) |
| Annual Dividend Forecast | ¥18 → ¥19（+5.6%） |
| Segment revenue | API sales business ¥3,952 million (YoY -2.1%) / Pharmaceutical manufacturing and marketing business ¥2,082 million (YoY -6.8%) |
| Segment profit | API sales business ¥726 million (YoY -13.6%) / Pharmaceutical manufacturing and marketing business ¥374 million (YoY -31.7%) |
| Depreciation and amortization | 148,808 Thousands of yen |
| Impairment loss | No applicable matters |
| Breakdown of extraordinary income (loss) | No applicable matters |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | 0 additions and 0 exclusions (no company names) |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 42,119,980 Shares |
| Treasury Shares at Period-End | 1,476 Shares |
| Factors Behind Changes in Business Performance | In the active pharmaceutical ingredients sales business, sales of products for cardiovascular and sensory organ applications, among others, declined, while in the pharmaceutical manufacturing and marketing business, sales of tablets for core products decreased. Meanwhile, sales of prefilled syringe products and other products increased. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the active pharmaceutical ingredients sales business, sales of active pharmaceutical ingredients for cardiovascular and sensory organ applications, among others, declined, while in the pharmaceutical manufacturing and marketing business, sales of tablets for core products decreased. Meanwhile, sales of prefilled syringe products and other products increased.